Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Cutaneous Malignant Melanoma Clinical Trial

— NIPAWILMA  

Official title:

Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02308553
• Other study ID #: Nipawilma_2013
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 17, 2015
• Est. completion date: November 2019

Study information

• Verified date: October 2020
• Source: University Hospital, Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase I/II trial designed to characterize the safety and estimate the efficacy of nintedanib when combined with paclitaxel chemotherapy compared with paclitaxel chemotherapy alone in patients with BRAF wild type metastatic melanoma not previously treated with taxanes or kinase inhibitors.

Description:

Study Phase I: Run-In-Phase Based on acceptable safety data for nintedanib monotherapy, a rapid dose finding will be conducted in a classical 3+3 design. Predefined dose levels are 150 mg (dose level 1) and 200 mg (dose level 2) nintedanib, twice daily, with weekly paclitaxel 90 mg/m2.

Study Phase II Patients with advanced (unresectable Stage III or IV) BRaf V600 wild type melanoma (n=120) will be randomized (1:1) to receive either Nintedanib (150 or 200 mg BID depending on results of phase I) in combination with paclitaxel or Placebo in combination with paclitaxel.

Total study duration per patient: approximately 12 months of therapy + Follow up until end of study

All patients enrolled in either phase I or phase II will be treated according to the following treatment plan:

Week 1 - 24:

Chemotherapy with paclitaxel combined with nintedanib/placebo

Week 25 - 48:

Extended monotherapy with nintedanib/placebo

Week 52 (or approximately 4 weeks after last treatment dose):

End of Treatment visit

Follow up:

After end of treatment the survival, disease status and further therapies of each patient will be assessed every 3 months until death, progression of disease or end of study whichever occurs first

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: November 2019
• Est. primary completion date: October 17, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed, (surgically incurable or unresectable) stage III or IV, BRAF V600 wildtype metastatic cutaneous malignant melanoma.

2. Written informed consent

3. A minimum of 1 measurable lesion according to RECIST v1.1 criteria.

4. ECOG of 0-1.

5. Adequate hematologic, renal and liver function within 14 days prior to initiation of dosing:

• Hematologic:

• Absolute neutrophil count (ANC) =1.5 x 109/L

• Hemoglobin = 9 g/dL (5.6 mmol/L; Subjects may not have had a transfusion within 7 days of screening assessment)

• Platelets: = 100 x 109/L

• Hepatic

• Total bilirubin: = 1.0 x ULN

• AST and ALT: = 1.5 x ULN (In the case of liver metastases: 2.5 x ULN)

• Renal o Serum creatinine: = 1.5 mg/dL (133 µmol/L) or, if greater than 1.5 mg/dL:

Calculated creatinine clearance: = 50 mL/min

6. effective method of contraception for at least 3 months after completion of nintedanib/placebo monotherapy as directed by their physician.

7. Men should use an effective method of contraception during treatment and for at least 6 months after completion of paclitaxel treatment and for at least 3 months after completion of nintedanib/placebo monotherapy as directed by their physician.

8. Patients must have recovered from all prior treatment-related toxicities to NCI CTCAE (v4.0) Grade of 0 or 1, except for toxicities not considered a safety risk such as alopecia.

9. Male or female, aged 18 years or older

10. Life expectancy at least 3 months

Exclusion Criteria:

1. Prior systemic therapy with taxanes or kinase inhibitors. Any prior therapy for metastatic disease must have been discontinued at least 4 weeks prior to initiation of dosing.

2. Major surgery or radiation therapy within 4 weeks of starting the study treatment (minor surgical procedures such as biopsies are allowed, however patients must have recovered).

3. Known inherited predisposition to bleeding or thrombosis and therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325mg per day)

Patients with the following coagulation parameters will be excluded:

• International normalised ratio (INR) > 2

• Prothrombin time (PT) and partial thromboplastin time (PTT): > 50% of deviation of institutional ULN

4. History of clinically significant haemorrhagic or thromboembolic event in the past 6 months

5. NCI CTCAE (V4.0) grade 3 hemorrhage within 4 weeks of starting the study treatment.

6. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to randomization.

7. Serious, non-healing wound, ulcer, or bone fracture.

8. Known CNS disease:

• Previous Grade 2 or higher sensory neuropathy.

• History of or known spinal cord compression, or carcinomatous meningitis, or evidence of active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomization) or leptomeningeal disease on screening CT or MRI scan.

9. Any of the following within the 6 months prior to enrolment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.

10. New York Heart Association (NYHA) Grade II or greater congestive heart failure.

11. Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.0 grade = 2.

12. Inadequately controlled hypertension (defined as systolic blood pressure > 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications).

13. Symptomatic peripheral vascular disease.

14. Proteinuria at screening as demonstrated by urine dipstick for proteinuria = 2+ (patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate = 1g of protein in 24 hours to be eligible).

15. Known hypersensitivity reaction to any of the components of study treatment (e.g. contrast media) or other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

16. Previous cancer (unless a RFS interval of at least 5 years) with the exception of surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.

17. Known clinically uncontrolled infectious disease including HIV positivity or AIDS-related illness and active or chronic hepatitis C and/or B infection.

18. Pregnancy (absence to be confirmed by ß-hCG test) or lactation period.

19. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule

20. Active alcohol or drug abuse

21. Treatment with other investigational drugs or treatments in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial.

22. Legal incapacity or limited legal capacity

23. Significant weight loss (> 10% of body weight) within past 6 months prior to inclusion into the trial

Related Conditions & MeSH terms

• Cutaneous Malignant Melanoma
• Melanoma

Intervention

Drug:
• Nintedanib
Nintedanib (150 mg or 200 mg BID)
• Nintedanib-Placebo
Placebo (150 mg or 200 mg BID)
• Paclitaxel
Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)

Locations

Country	Name	City	State
Germany	Elbeklinikum Buxtehude	Buxtehude
Germany	University Hospital Essen	Essen	NRW
Germany	SRH Wald-Klinikum Gera	Gera
Germany	National Centre for Tumour Diseases (NCT)	Heidelberg
Germany	Universitätsklinikum des Saarlandes	Homburg
Germany	Universitätsklinikum Schleswig-Holstein, Campus Lübeck	Lübeck
Germany	Klinikum der Stadt Ludwigshafen am Rhein gGmbH	Ludwigshafen
Germany	University Hospital München	München
Germany	Fachklinik Hornheide	Münster
Germany	University Hospital Münster	Münster

Sponsors (4)

Lead Sponsor	Collaborator
Prof. Dr. med. Dirk Schadendorf	Alcedis GmbH, Boehringer Ingelheim, medac GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival (PFS)	Time from administration of first study drug to the date of first documented progression or death due to any cause, whichever occurs first	12 months after LPI
Secondary	Overall survival	Time from the date of first administration of study drug to the date of death due to any cause.	12 months after LPI
Secondary	Safety and toxicity (graded according to CTCAE, Version 4.0)	Reporting of adverse events from the date of first administration of study drug until 30 days after last administration of study drug	12 months after LPI
Secondary	Quality of Life (EORTC QLQ-C30)	Quality of life during therapy (i.e. until end of treatment visit)	12 months after LPI